Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome

Sherman M Chamberlain, Satish Sanku Chander Rao

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Lubiprostone is approved in the United States for the treatment of chronic idiopathic constipation and constipation predominant irritable bowel syndrome (IBS-C). Lubiprostone causes secretion of fluid and electrolytes in the small bowel, through the activation of chloride channels, and thereby induces laxation and improvement of bowel functions. It is generally considered to be safe and effective. Common side effects of lubiprostone include nausea, diarrhea, abdominal pain and bloating, and the rare side effect dyspnea. Likely mechanisms for these side effects may be related to lubiprostone's primary action on small bowel secretion and the associated intestinal distension, as well as smooth muscle contraction. Areas covered: This article reviews the pharmacokinetic and safety profile of lubiprostone, with particular relevance to the two FDA-approved dosages. Expert opinion: Lubiprostone acts topically in the gut lumen and is almost completely metabolized in the gut lumen. Lubiprostone's M3 metabolite can be detected in low concentrations in the serum and may be responsible for some of its side effects. However, the exact mechanisms by which the side effects are produced are currently unknown.

Original languageEnglish (US)
Pages (from-to)841-850
Number of pages10
JournalExpert Opinion on Drug Safety
Volume11
Issue number5
DOIs
StatePublished - Sep 1 2012

Fingerprint

Irritable Bowel Syndrome
Constipation
Safety
Therapeutics
Intestinal Secretions
Fluids and Secretions
Chloride Channels
Expert Testimony
Muscle Contraction
Lubiprostone
Dyspnea
Nausea
Abdominal Pain
Electrolytes
Smooth Muscle
Diarrhea
Pharmacokinetics
Serum

Keywords

  • chronic idiopathic constipation
  • intestinal secretion
  • irritable bowel syndrome
  • lubiprostone

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome. / Chamberlain, Sherman M; Rao, Satish Sanku Chander.

In: Expert Opinion on Drug Safety, Vol. 11, No. 5, 01.09.2012, p. 841-850.

Research output: Contribution to journalReview article

@article{a63c0faa44954bf4aa17c6e54450c5a3,
title = "Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome",
abstract = "Lubiprostone is approved in the United States for the treatment of chronic idiopathic constipation and constipation predominant irritable bowel syndrome (IBS-C). Lubiprostone causes secretion of fluid and electrolytes in the small bowel, through the activation of chloride channels, and thereby induces laxation and improvement of bowel functions. It is generally considered to be safe and effective. Common side effects of lubiprostone include nausea, diarrhea, abdominal pain and bloating, and the rare side effect dyspnea. Likely mechanisms for these side effects may be related to lubiprostone's primary action on small bowel secretion and the associated intestinal distension, as well as smooth muscle contraction. Areas covered: This article reviews the pharmacokinetic and safety profile of lubiprostone, with particular relevance to the two FDA-approved dosages. Expert opinion: Lubiprostone acts topically in the gut lumen and is almost completely metabolized in the gut lumen. Lubiprostone's M3 metabolite can be detected in low concentrations in the serum and may be responsible for some of its side effects. However, the exact mechanisms by which the side effects are produced are currently unknown.",
keywords = "chronic idiopathic constipation, intestinal secretion, irritable bowel syndrome, lubiprostone",
author = "Chamberlain, {Sherman M} and Rao, {Satish Sanku Chander}",
year = "2012",
month = "9",
day = "1",
doi = "10.1517/14740338.2012.708732",
language = "English (US)",
volume = "11",
pages = "841--850",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome

AU - Chamberlain, Sherman M

AU - Rao, Satish Sanku Chander

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Lubiprostone is approved in the United States for the treatment of chronic idiopathic constipation and constipation predominant irritable bowel syndrome (IBS-C). Lubiprostone causes secretion of fluid and electrolytes in the small bowel, through the activation of chloride channels, and thereby induces laxation and improvement of bowel functions. It is generally considered to be safe and effective. Common side effects of lubiprostone include nausea, diarrhea, abdominal pain and bloating, and the rare side effect dyspnea. Likely mechanisms for these side effects may be related to lubiprostone's primary action on small bowel secretion and the associated intestinal distension, as well as smooth muscle contraction. Areas covered: This article reviews the pharmacokinetic and safety profile of lubiprostone, with particular relevance to the two FDA-approved dosages. Expert opinion: Lubiprostone acts topically in the gut lumen and is almost completely metabolized in the gut lumen. Lubiprostone's M3 metabolite can be detected in low concentrations in the serum and may be responsible for some of its side effects. However, the exact mechanisms by which the side effects are produced are currently unknown.

AB - Lubiprostone is approved in the United States for the treatment of chronic idiopathic constipation and constipation predominant irritable bowel syndrome (IBS-C). Lubiprostone causes secretion of fluid and electrolytes in the small bowel, through the activation of chloride channels, and thereby induces laxation and improvement of bowel functions. It is generally considered to be safe and effective. Common side effects of lubiprostone include nausea, diarrhea, abdominal pain and bloating, and the rare side effect dyspnea. Likely mechanisms for these side effects may be related to lubiprostone's primary action on small bowel secretion and the associated intestinal distension, as well as smooth muscle contraction. Areas covered: This article reviews the pharmacokinetic and safety profile of lubiprostone, with particular relevance to the two FDA-approved dosages. Expert opinion: Lubiprostone acts topically in the gut lumen and is almost completely metabolized in the gut lumen. Lubiprostone's M3 metabolite can be detected in low concentrations in the serum and may be responsible for some of its side effects. However, the exact mechanisms by which the side effects are produced are currently unknown.

KW - chronic idiopathic constipation

KW - intestinal secretion

KW - irritable bowel syndrome

KW - lubiprostone

UR - http://www.scopus.com/inward/record.url?scp=84865498099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865498099&partnerID=8YFLogxK

U2 - 10.1517/14740338.2012.708732

DO - 10.1517/14740338.2012.708732

M3 - Review article

C2 - 22834474

AN - SCOPUS:84865498099

VL - 11

SP - 841

EP - 850

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 5

ER -